BackPulike Biological Engineering Overview

Pulike Biological Engineering Receivables

Track Pulike Biological Engineering's receivables ($410M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$407.08M
↑ 16.42% YoYΔ $57.40M vs prior year quarter

Peer trimmed avg / median

Loading

Pulike Biological Engineering Receivables History

Loading

Pulike Biological Engineering vs. peers: Receivables Comparison

Loading

Pulike Biological Engineering Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Pulike Biological Engineering (603566.SS) FAQ

Pulike Biological Engineering's receivables stands at $410M as of September 2026. That compares with $350M in the prior-year period — up 16.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Pulike Biological Engineering reported $410M in receivables versus $350M a year earlier — a 16.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $350M in the prior-year period — up 16.4% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Pulike Biological Engineering's receivables evolved across reporting periods, while the comparison chart places 603566.SS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Pulike Biological Engineering's reading of $410M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.